6d agoYahoo TopBULLISH 65M&A
Supernus and Indivior merge to create scaled, CNS-focused entity
Through this merger, the duo will combine their commercial medicinal portfolios, which span CNS and opioid use disorders (OUDs).
Archived explainer. For the current picture see today's SUPN page.
Why Is SUPERNUS PHARMACEUTI (SUPN) Stock Up Today?
By the Top Tier Newswire AI Desk · August 5, 2026 at 10:07 AM ET · reviewed against 6 wire stories
SUPERNUS PHARMACEUTI (SUPN) is up +9.15% in the latest session. Our newswire has captured 6 stories on SUPN across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why SUPN stock is up today
Supernus Pharmaceuticals shares surged 9.15% to $47.20 on Monday, driven by a combination of a revenue beat, a raised 2026 guidance, and the announcement of a merger with Indivior. The stock opened with a slight gap down but quickly reversed course, reaching a session high of $47.39 before settling near that level. The merger with Indivior, a proposed all-stock, tax-free transaction, is expected to create a combined CNS-focused biopharmaceutical company.
What Happened
The 8-K filing from Supernus on August 3 confirmed the merger with Indivior, which will combine their commercial portfolios targeting CNS and opioid use disorders. The companies are marketing nearly a dozen neurological drugs, and the merger is expected to create a stronger entity with potential annual revenue of $2 billion. Supernus also reported second-quarter revenue of $219.058 million, which beat estimates of $204.962 million. However, the company’s adjusted EPS of $0.53 was offset by a non-cash impairment charge that led to a reported EPS of $(1.01), missing the $0.07 estimate.
Retail traders on social platforms are discussing the stock as potentially oversold, and recent coverage from Yahoo Finance and Benzinga has highlighted the strategic and financial implications of the merger. The stock’s sharp intraday move reflects optimism about the combined entity’s potential and Supernus’ recent earnings performance.
What The Data Shows
The stock opened at $42.97, below the previous close of $43.25, but quickly reversed to a high of $47.39. Volume was 0.1 million shares, or 0.2 times the 3-month average. The stock has traded within a 52-week range of $35.51 to $59.68, and over the last 8 sessions, it declined 4.4% from $46.20 to $44.17. Supernus has a market cap of $2.7 billion, unprofitable with a TTM EPS of -1.91, and a revenue growth of 24.9% TTM. The stock has a beta of 0.56, indicating lower volatility than the market.
What To Watch
The next key event for Supernus will be the progression of the merger with Indivior. Investors should monitor the regulatory approval process and the integration of the two companies' portfolios. Coverage breadth is also a factor to watch, as the 6 stories from 4 sources in the last 36 hours suggest growing interest in the stock.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SUPN by the numbers
Last: $47.20Session: +9.15%7 sessions: -0.15%Coverage: 6 stories / 4 sourcesAI sentiment: 60/100 (bullish)Mkt cap: $2.7B52w: $35.51 to $59.68
The headlines behind the move
7d agoSEC 8-KNEUTRAL 50General
SUPERNUS PHARMACEUTICALS, INC. (SUPN) files 8-K
Filed: 2026-08-03 AccNo: 0001104659-26-089839 Size: 2 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
7d agoBarchartNEUTRAL 50General
Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders?
7d agoYahoo TopBULLISH 63M&A
Supernus Pharmaceuticals Q2 Earnings Call Highlights
Supernus Pharmaceuticals (NASDAQ:SUPN) and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing 12-month net revenue as of June 30, 2026.
7d agoYahoo FinanceBULLISH 73M&A
Supernus Shares Jump After Revenue Beat, Higher Guidance and Indivior Merger Announcement
Supernus beat second-quarter revenue estimates, raised its 2026 guidance and announced a merger with Indivior, sending shares sharply higher despite an earnings miss driven by a non-cash impairment charge.
7d agoYahoo TopBULLISH 58M&A
Supernus, Indivior merge to beef up brain drug portfolio
The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on SUPN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier SUPN move explainers: 2026-08-05 · 2026-08-03